This interesting article from Harvard Business Review cites importance of Agile in a life sciences company. Estimated cost for each new approved drug is in the range of $1.5 to $2.0 billion, so it makes all the sense to use agile science which is a new way of working characterized by the pragmatic and context-specific use of agile methods and tools.
PTC therapeutics quadrupled the number of planned research and clinical development projects in 24 months due to its ballooning R&D investments and pipeline.
What are your thoughts?
